Biotech business receives authorisation for transformational solution

Aquaculture and biotechnology company Benchmark has received marketing authorisation from the Norwegian Medicines Agency (NoMA) for its transformational solution to a leading salmon farming problem – sea lice.

The Sheffield-based business believes that its Ectosan® Vet (product code name BMK08) can support sustainable growth by reducing the economic and operational impact of sea lice – which costs the salmon farming industry more than $1bn annually, and c.$600m in Norway alone.

The product which is sea lice veterinary medicinal treatment to be introduced to the Norwegian salmon market in over a decade. also expected to first whilst improving fish welfare and protecting the environment.

This approval from NoMA follows Benchmark announcing its first customer agreements for its CleanTreat product in March and based on the market authorisation on both Ectosan Vet and CleanTreat it is expected to be profitable from the outset.

Trond Williksen, CEO of Benchmark said: “We are pleased to have received Marketing Authorisation from the Norwegian Medicines Agency, which represents a major milestone for the Company. It is testament to the team of scientists at Benchmark that we are able to bring the first new sea lice veterinary medicinal treatment to the Norwegian salmon market in over a decade.

“We are excited to bring this much needed solution to the salmon industry, driving sustainability through improved animal welfare and yield while protecting the environment.

“We look forward to working with our customers as we roll-out Ectosan Vet and CleanTreat in the market.”